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a  b  s  t  r  a  c  t
Tumor  associated  macrophages  (TAM)  support  tumor  growth  and metastasis  in several  animal  models  of
breast  cancer,  and  TAM  amount  is  predictive  for efﬁcient  tumor  growth  and metastatic  spread  via blood
circulation.  However,  limited  information  is available  about  intratumoral  TAM  heterogeneity  and  func-
tional  role  of TAM  subpopulations  in  tumor  progression.  The  aim  of  our study was  to examine  correlation
of  TAM  presence  in  various  morphological  segments  of  human  breast  cancer  with  clinical  parameters.
Thirty  six  female  patients  with  nonspeciﬁc  invasive  breast  cancer  T1-4N0-3M0  were  included  in  the  study.
Morphological  examination  was  performed  using  Carl  Zeiss  Axio Lab.A1  and  MiraxMidiZeiss.  Immunohis-
tochemical  and  immunoﬂuorescence/confocal  microcopy  analysis  was  used  to detect  CD68  and  stabilin-1
in 5 different  tumor  segments:  (1)  areas  with  soft  ﬁbrous  stroma;  (2)  areas  with  coarse  ﬁbrous  stroma;
(3)  areas  of maximum  stromal-and-parenchymal  relationship;  (4)  parenchymal  elements;  (5) gaps  of
ductal  tumor  structures.  The  highest  expression  of CD68  was in  areas  with  soft  ﬁbrous  stroma  or  areas
of maximum  stromal-and-parenchymal  relationship  (79%).  The  lowest  expression  of CD68  was  in  areas
with coarse  ﬁber  stroma  (23%).  Inverse  correlation  of  tumor  size  and  expression  of  CD68  in gaps  of  tubu-
lar tumor  structures  was  found  (R  =  −0.67;  p =  0.02). In case  of  the  lymph  node  metastases  the  average
score  of  CD68  expression  in  ductal  gaps  tumor  structures  was  lower  (1.4  ± 0.5)  compared  to  negative
lymph  nodes  case  (3.1  ±  1.0;  F  =  10.9;  p = 0.007).  Confocal  microscopy  identiﬁed  3 phenotypes  of  TAM:
CD68+/stabilin-1−; CD68+/stabilin-1+ (over  50%);  and  CD68−/stabilin-1+.  However,  expression  of  stabilin-
1  did  not  correlate  with  lymph  node  metastasis.  We  concluded,  that  increased  amount  of  CD68+TAM  in
gaps  of  ductal  tumor  structures  is protective  against  metastatic  spread  in  regional  lymph  nodes.
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. Introduction
The supportive role of tumor associated macrophages (TAM) for
umor progression was primarily demonstrated in animal breast
ancer models (Noy and Pollard, 2014). It was established that
AM belong to alternatively activated macrophages and can sup-
ort tumor growth and metastasis using multiple mechanisms. For
nstance, TAM support survival and induce motility of breast can-
er cells by producing epidermal growth factor (EGF) (Goswami
t al., 2005). In spontaneous and ectopic models of breast cancer
AM produce pro-angiogenic factors such as VEGF-A contributing
o angiogenesis and progression to malignancy, tumor cell growth
nd dissemination (Noy and Pollard, 2014; Gazzaniga et al., 2007;
in et al., 2006; Sierra et al., 2008). Simultaneously with release
f pro-angiogenic factors, the ability of TAM to produce matrix-
egrading enzymes (MMP-2, MMP-9, uPA, cathepsins) and tumor
ell-recruiting factors such as CCL-18 is associated with stimula-
ion of breast tumor cell invasiveness and metastatic spread (Chen
t al., 2011; Gocheva et al., 2010; Qian and Pollard, 2010). Moreover,
AM closely associate with blood vessels and promote tumor cells
ntravasation resulting in their escape into circulation and forma-
ion of distant metastases (Qian and Pollard, 2010; Pollard, 2008;
yckoff et al., 2007).
However, in humans, not only positive but also negative corre-
ations between TAM and various parameters of tumor growth and
pread were demonstrated indicating much more complex mech-
nism of tumor cell-microenvironmental crass-talk. TAM density
n different cancers is associated with incidence of distant metas-
ases. TAM inﬁltration has positive or inverse correlation with
etastases depending on tumor type. For example, high inﬁltra-
ion by CD68+ TAM was associated with higher risk of distant
etastases in triple-negative breast cancer (Yuan et al., 2014). In
ddition, higher numbers of histological structures named tumor
icroenvironment for metastasis (TMEM) that represent close
ssociation of CD68+ macrophages, endothelial, and invasive tumor
ells was associated with higher risk of distant metastasis in
R+/HER2–breast cancer (Rohan et al., 2014). In contrast, TAM inﬁl-
ration was associated with suppression of metastases in high grade
steosarcoma (Buddingh et al., 2011). Similarly, higher density of
D68+ TAM was associated with lower incidence of hepatic metas-
ases in colon cancer (Zhou et al., 2010).
In terms of lymphatic metastasis, mostly supportive role of
AM was demonstrated. For example, positive correlation between
verall density of CD68+ TAM and lymph node (LN) metastases
as found in human papillary thyroid carcinoma, endometrial can-
er, cervical cancer, pulmonary adenocarcinoma, gastric cancer,
reast cancer and others (Ding et al., 2012; Ohno et al., 2004;
ing et al., 2012; Riabov et al., 2014; Schoppmann et al., 2002;
akanami et al., 1999; Wu et al., 2012). Detrimental role of TAM
n lymphatic metastases was mainly associated with their abil-
ty to produce pro-lymphangiogenic factors VEGF-C and VEGF-D
hat induce growth of intratumoral lymphatic vessels (Riabov et al.,
014; Iwata et al., 2007; Schoppmann et al., 2006; Song et al., 2013;
ang et al., 2011). They also release matrix-remodeling enzymes
ncluding MMP-2, MMP-9, and urokinase plasminogen activator
uPA) known to contribute to lymphangiogenesis (Riabov et al.,
014). Pro-lymphangiogenic and pro-metastatic properties of TAM
ere linked to their M2-like phenotype with preferential produc-
ion of IL-10, CCL-18, and CCL-22 (Chen et al., 2011; Qing et al.,
012; Tsujikawa et al., 2013).
However, in the majority of studies only overall density of CD68+
AM was analyzed and associated with LN metastases (Riabov
t al., 2014). Insufﬁcient attention was given to the intratumoral
eterogeneity of TAM subtypes, in particular in relation to the dif-
erent intratumoral structures. In human breast cancer following
ntratumoral compartments can be deﬁned: (1) areas with softology 222 (2017) 31–38
ﬁbrous stroma characterized by pronounced inﬂammatory inﬁl-
trates that are beneﬁcial for invasive cell growth (Ham and Moon,
2013); (2) areas with coarse ﬁbrous stroma containing collagen
ﬁbers and characterized by impaired synthesis of extracellular
matrix proteins (ECM) (Campbell et al., 2011; Eiro et al., 2012;
Ruffell et al., 2012; Tang, 2013); (3) areas of maximum stromal-
and-parenchymal relationship revealing certain similarities with
soft ﬁbrous stroma (Mahmoud et al., 2012); (4) parenchymal ele-
ments; (5) gaps of ductal tumor structures (Pinder, 2010). All
ﬁve stromal subtypes demonstrate functionally distinct areas of
tumor mircoenvironment with not yet identiﬁed mechanistic role
in metastatic spread.
In the present study we assessed the distribution of TAM in ﬁve
distinct intratumoral morphological compartments and examined
the correlation with clinical parameters of tumor progression. For
the ﬁrst time we  demonstrated that amount of CD68+ macrophages
in gaps of tubular tumor structures has negative correlation with
lymph node metastasis. The highest amount of CD68+macrophages
was present in the areas of soft ﬁbrous stroma or areas of maximum
stromal-and-parenchymal relationship (79%). We  also identiﬁed
three phenotype of TAM: CD68+/stabilin-1−; CD68+/stabilin-1+
(over 50%); and CD68−/stabilin-1+. However, expression of stabilin-
1 did not correlate with lymph node metastasis. Our data suggested
that increased amount of CD68 + TAM in gaps of ductal tumor struc-
tures is protective against metastatic spread in regional lymph
nodes, and that these metastasis-protective TAM do not depend
on pronounced M2-like activation.
2. Materials and methods
2.1. Patients
Thirty six female patients with nonspeciﬁc invasive breast
cancer T1-4N0-3M0, who were treated in General Oncology
Department of Tomsk Cancer Research Institute (Tomsk, Russia)
from January 1999 to January 2007, were included in the present
study. The study was approved by the Local Committee for Med-
ical Ethics of our Institute (protocol No. 13 from 09.27.2014), and
informed consents were obtained from all patients prior to anal-
ysis. Patients did not receive preoperative treatment. The mean
age of women with breast cancer was  60.8 ± 11.3 years. Menstrual
function was preserved in 7 (19%) patients, 29 women (81%) had
menopause. The histological type of breast cancer was deﬁned
according to the WHO  recommendations (Geneva, 2012) and cor-
responded to nonspeciﬁc invasive carcinoma in all cases.
2.2. Antibodies
The following primary antibodies were used: mouse mono-
clonal anti-human CD68 (BD Biosciences) and rabbit polyclonal
anti-stabilin-1 RS1 (Kzhyshkowska et al., 2008). Super Sensitive
Polymer-HRP detection system was  used for immunohistochemical
analysis (BioGenex, USA). Secondary antibodies for immunoﬂuo-
rescent staining were conjugated with Alexa488 (anti-mouse) and
with Cy3 (anti-rabbit) (Dianova).
2.3. Immunohistochemical analysis
Fresh tumor tissues were ﬁxed in 10% neutral formalin (Karbolit,
Russia) for 24 h, rinsed with mixture of isopropanol (Biovitrum,
Russia), and embedded in parafﬁn (Biovitrum, Russia). The anti-
gen unmasking was  performed using the PT Link module (Dako,
Denmark) in a buffer with a high pH value. To visualize the antigen-
antibody reaction, the Super Sensitive Polymer-HRP detection
system was used (BioGenex, USA). Immunohistochemical analy-
sis was performed by light microscope «Carl Zeiss Axio Lab.A1»
unobio
(
(
a
d
t
d
ﬁ
6
i
2
w
A
I
p
i
t
s
n
t
a
3
2
S
n
w
C
a
a
m
t
L
Z
4
l
L
a
2
W
S
n
w
3
3
C
t
i
t
m
n
r
T
cM. Buldakov et al. / Imm
Jenamed, Carl Zeiss, Germany) and slidescanner «MiraxMidiZeiss»
Germany). The results of the immunohistochemical analysis were
ssessed as the percentage of positively stained cells with any
egree of positive marker expression in different parts of the sec-
ion (1000 cells in 10 ﬁelds of view). Positive expression was
etermined by a 4-point scale: 1 point (+) – 1– cells in the view
eld; 2 points (++) – 3–5 cells in the view ﬁeld; 3 points (+++) –
–10 cells in the view ﬁeld and 4 points (++++) – more than 10 cells
n the view ﬁeld (×400)
.4. Digital IHC analysis and quantiﬁcation
Tumor slides were scanned using the NIS Elements Imaging Soft-
are (Nikon, Japan). The Aperio ImageScope software (free from
perio.com) was used to analyze and quantify marker expression.
ndividual tumor regions were selected and analyzed using the
ositive pixel count algorithm. The ImageScope software makes
t possible to set the threshold for color saturation, as well as
he upper and lower limits for the intensities of the weak- and
trong-positive pixels. These thresholds were set using positive and
egative control tissues. The results of analysis presented as posi-
ivity (number of positive pixels in a selected region to number of
ll pixels). Total number of analyzed samples were 24 for CD68 and
3 for RS1.
.5. Immunoﬂuorescent staining and confocal microscopy
Deparafﬁnization was performed with xylene and ethanol.
amples were blocked with 3% BSA in PBS, incubated with a combi-
ation of primary antibodies for 1 h, 15 min, washed, and incubated
ith a combination of appropriate secondary antibodies. Anti-
D68 and anti-stabilin-1 primary antibodies were used at a 1:100
nd 1:1000 dilution correspondingly. Anti-mouse Alexa488 labeled
nd anti-rabbit Cy3 were used at 1:100 dilution. Samples were
ounted with immunoﬂuorescence mounting medium (DakoCy-
omation, Carpinteria, CA) and analyzed by confocal microscopy.
Confocal laser-scanning microscopy was performed using a
eica TCS SP2 laser-scanning spectral confocal microscope and Carl
eiss LSM 780 NLO. Excitation was with an argon laser, emitting
88 nm;  a krypton laser, emitting at 568 nm;  and a helium/neon
aser, emitting at 633 nm.  Data were acquired and analyzed with
eica confocal software. All two- or three-color images were
cquired using a sequential scan mode.
.6. Statistical analysis
Statistical analysis was performed using STATISTICA 8.0 for
indows (StatSoft Inc., USA). The ANOVA, Chi-square test and
pearman correlation analysis were implemented. Statistical sig-
iﬁcance was set at p value <0.05, with a two-tail approach. Data
ith marginal signiﬁcance (p value <0.1) were also discussed.
. Results
.1. Subpopulations of TAM in human breast cancer according to
D68 and stabilin-1 expression
It is widely accepted that tumor cells program TAM to acquire
olerogenic M2-like phenotype in order to inhibit anti-tumor
mmune responses and to promote tumor growth and metas-
asis. Stabilin-1 was shown by us to be marker for M2-type of
acrophages that mediates clearance of unwanted-self compo-
ents (Kzhyshkowska et al., 2008; Kzhyshkowska et al., 2006b;
eviewed in Kzhyshkowska, 2010; Kzhyshkowska et al., 2006a).
herefore we examined whether TAM in human breast can-
er express stabilin-1 on CD68+ macrophages. Using doublelogy 222 (2017) 31–38 33
immunoﬂuorescence and confocal microscopy we demonstrated
that stabilin-1 is abundantly expressed in TAM; and according to
the CD68 and stabilin-1 positivity we  could distinguish 3 subpopu-
lations of TAM: CD68+/stabilin-1−; CD68+/ stabilin-1+; and CD68−/
stabilin-1+ (Fig. 1, Supplementary Fig. S1). Majority of macrophages
were CD68+, while around 50% of macrophages expressed stabilin-
1. Therefore further quantitative immunohistochemical evaluation
of the correlation of CD68 and stabilin-1, present in distinct mor-
phological structures with clinical parameters has been performed
separately for CD68 and for stabilin-1.
3.2. CD68 and stabilin-1 expression in ﬁve distinct intratumoral
compartments of nonspeciﬁc invasive breast cancer
In order to examine whether CD68+ and stabilin-1+ TAM are dif-
ferentially presented in ﬁve intratumoral compartments of breast
cancer, immunohistochemical analysis of parafﬁn-embedded sec-
tions obtained from thirty six female patients with nonspeciﬁc
invasive breast cancer was  performed. We  examine amounts of
CD68+ and stabilin-1+ cells in following morphologically and func-
tionally distinct areas of tumors (1) in areas with soft ﬁbrous stroma
(Fig. 2); (2) in areas with coarse ﬁbrous stroma (Fig. 3); (3) in
the areas of the so-called “maximum stromal-and-parenchymal
relationship” where the individual tumor cells, short strands and
groups of tumor cells arranged in soft ﬁbrous stroma (Fig. 4); (4)
among parenchymal elements (Fig. 5); (5) in gaps of ductal tumor
structures (Fig. 6).
The highest expression (4 points or ++++) of CD68 in the inﬂam-
matory cell inﬁltrate was  detected most frequently in areas with
soft ﬁbrous stroma (54% of analysed patients) or the so-called “max-
imum stromal-and-parenchymal relationship” (79%) in patients
with breast cancer. The lowest expression (1 point or +) of CD68 was
observed more frequently in areas with coarse ﬁber stroma (23%).
The CD68-positive cells of the inﬂammatory inﬁltrate were absent
often between parenchymal elements of tumor (88%) (Table 1,
Figs. 2–6). For stabilin-1, the highest expression was  found in maxi-
mum  stromal-and-parenchymal relationship (44%), and the lowest
in coarse ﬁbrous stroma (13%), indicating that CD68 and stabilin-1
independently correlate with intratumoral morphological com-
partments (Table 2, Figs. 2–6).
3.3. Association of CD68 and stabilin-1 in ﬁve distinct
intratumoral compartments and parameters of tumor growth
In order to examine the correlation between amount of CD68+
and stabilin-1+ cells in distinct intratumoral compartments, tumors
size and grade of tumor malignancy were examined. We  found
inverse correlation (R = −0.67; p = 0.02) between tumor size and
the expression of CD68 in the cells of the inﬂammatory inﬁltrate
in gaps of tubular tumor structures (Table 3). The CD68 expres-
sion in the inﬂammatory cell inﬁltrate of the other tumor areas
did not show signiﬁcant correlation with tumor size (Table 3). No
signiﬁcant correlation was  found between the CD68 expression in
the inﬂammatory cell tumor inﬁltrate and the rate of tumor malig-
nancy (Table 4). Presence of stabilin-1+ cells also had no signiﬁcant
correlation with tumor size or malignancy.
3.4. Correlation of CD68 and stabilin-1 with lymphatic metastasis
In order to further asses the role of TAM in progression of
breast cancer we evaluated correlation with CD68+ and stabilin-
1+ cells in lymphatic metastasis by detecting metastatic lesion in
distant lymph nodes. We  found, that amount of CD68+ TAM neg-
atively correlated with the presence of metastatic regional lymph
nodes. In the case of the lymph node metastases the average score
of CD68 expression in cells of ductal gaps tumor structures was
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Fig. 1. Subpopulations of CD68+ and stabilin-1+ TAM in patients with nonspeciﬁc invasive breast carcinoma. CD68 was  detected by immunoﬂuorescent staining using
a-CD68  mouse primary antibody and Alexa488- conjugated anti-mouse antibody (shown in green), stabilin-1 was  detected by RS1 rabbit polyclonal primary antibody and
Cy3-conjugated anti-rabbit secondary antibody (shown in red). Visualization of nuclei was performed using Dapi. Representative images are shown for CD68-/stabilin-1+
(A),  CD68+/stabilin-1- and CD68+/stabilin-1+ (B and C) subpopulations. Scale bars: 9,15 m (A); 8,86 m (B); and 5,42 m (C).
Fig. 2. Immunohistochemical analysis of CD68 and stabilin-1 expression in intratumoral compartment with soft ﬁber stroma in patients (n = 36) with nonspeciﬁc invasive
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isualization of nuclei was performed using hematoxylin. Representative image fro
ower (1.4 ± 0.5) in comparison with the negative lymph nodes case
3.1 ± 1.0; F = 10.9; p = 0.007) (Table 5). Amount of stabilin-1+ cells
id not show signiﬁcant correlation with the presence of lymphatic
etastasis.
In order to verify the negative correlation of CD68+ TAM with
ymphatic metastasis, we applied quantitative digital immunohis-
ology using Nikon Eclipse Ni Microscop and Aperio ImageScope
oftware. The Positivity of CD68 in gaps of ductal tumor structures
as higher (0.34 ± 0.4) for patients without lymph node metas-
ases compared to patients with lymphatic metastasis (0.1 ± 0.1)., clone 514H12). Stabilin-1 was visualized using rabbit polyclonal RS1 antibody.
 patient is shown. Scale bar 300 m (×400).
There were no signiﬁcant difference in the presence of stabilin-
1+ TAM in tumor section obtained from patients with or without
lymph node metastasis (0.05 ± 0.18 and 0.06±0.2 correspondently)
(Table 6). Thus, the results of quantitative ImageScope analysis
conﬁrmed the results of conventional immunohistological quan-
tiﬁcation (Tables 5 and 6). For the ﬁrst time it was  demonstrated
that the presence of CD68+ TAM in ductal tumor structures has
negative effect on the metastatic spread via lymphatic pathway in
breast cancer patients. Moreover, this effect was independent of
M2 phenotype acquisition.
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Fig. 3. Immunohistochemical analysis of CD68 and stabilin-1 expression in intratumoral compartment with coarse ﬁber stroma in patients (n = 36) with nonspeciﬁc invasive
breast  carcinoma. CD68 was visualized using mouse monoclonal antibody (Novocastra, clone 514H12). Stabilin-1 was visualized using rabbit polyclonal RS1 antibody.
Visualization of nuclei was  performed using hematoxylin. Representative image from one patient is shown. Scale bar 300 m (×400).
Fig. 4. Immunohistochemical analysis of CD68 and stabilin-1 expression in the intratumoral compartment with “maximum stromal and parenchymal cooperation” in
patients (n = 36) with nonspeciﬁc invasive breast carcinoma. Representative image is demonstrated. CD68 was visualized using mouse monoclonal antibody (Novocastra,
clone  514H12). Stabilin-1 was detected using rabbit polyclonal RS1 antibody. Visualization of nuclei was performed using hematoxylin. Representative image from one
patient  is shown. Scale bar 300 m (×400).
Fig. 5. Immunohistochemical analysis of CD68 and stabilin-1 expression intratumoral compartment between parenchymal structures in patients (n = 36) with nonspeciﬁc
invasive breast carcinoma. Representative image is demonstrated. CD68 was detected using mouse monoclonal antibody (Novocastra, clone 514H12). Stabilin-1 was  detected
using  rabbit polyclonal RS1 antibody. Visualization of nuclei was  performed using hematoxylin. Representative image from one patient is shown. Scale bar 300 m (×400).
Fig. 6. Immunohistochemical analysis of CD68 and stabilin-1 expression in inﬂammatory inﬁltrate cells in gaps of ductal-like structures in patients (n = 36) with nonspeciﬁc
invasive breast carcinoma. CD68 was visualized using mouse monoclonal antibody (Novocastra, clone 514H12). Stabilin-1 was visualized using Stabilin-1 was detected using
rabbit  polyclonal RS1 antibody. Visualization of nuclei was performed using hematoxylin. Representative image from one patient is shown. Scale bar 300 m (×400).
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Table 1
The CD68 expression in the inﬂammatory cell inﬁltrate in patients with the nonspeciﬁc invasive breast cancer.
Localization CD68 expression, the number of patients, in abs. (%)
No 1 point 2 points 3 points 4 points
In soft ﬁbrous stroma 1 4/35
(11%)
1/35
(3%)
8/35
(23%)
3/35
(9%)
19/35 (54%)
р2 = 0.0001
р4 = 0.0000
р5 = 0.0002
In  coarse ﬁbrous stroma 2 6/31
(19%)
7/31 (23%) 12/31
(39%)
3/31
(9.5%)
3/31
(9.5%)р1 = 0.008
р5 = 0.06
“Maximum stromal-and-parenchymal relationship” 3 1/14
(7%)
– 1/14
(7%)
1/14
(7%)
11/14 (79%)
р2 = 0.0000
р4 = 0.0000
р5 = 0.0000
Among  parenchymal elements 4 32/36 (88%) – 1/36
(3%)
1/36
(3%)
2/36
(6%)р1 = 0.0000
р2 = 0.0000
р3 = 0.0000
In  gaps of ductal tumor structures 5 22/34 (65%) 3/34 (9%) 5/34 (14%) – 4/34 (12%)
Table 2
Expression of stabilin-1 in the inﬂammatory cell inﬁltrate in patients with the nonspeciﬁc invasive breast cancer.
Localization Stabilin-1 expression, the number of patients, in abs. (%)
No 1 point 2 points 3 points 4 points
In soft ﬁbrous stroma 1 13/35 (37%) 2/35 (6%) 8/35 (23%) 5/35 (14%) 7/35 (20%)
In  coarse ﬁbrous stroma 2 20/31 (63%) 4/31 (13%) 3/31 (9%) 2/31 (6%) 3/31 (9%)
р1 = 0,01
“Maximum stromal-and-parenchymal relationship” 3 4/9 (44%) 1/9 (12%) – – 4/9 (44%)
р1 = 0,07
р2 = 0,009
р5 = 0,001
Among  parenchymal elements 4 33/36 (91%) 2/36 (6%) 1/36 (3%) – –
р1 = 0,0000
р3 = 0,001
In  gaps of ductal tumor structures 5 27/30 (90%) 2/30 (6,5%) – – 1/30 (3,5%)
р1 = 0,0000
р3 = 0,002
Table 3
The correlation of CD68 and stabilin-1 expression with tumor size in patients with the nonspeciﬁc invasive breast cancer.
Macrophage marker expression Tumor size
CD68 Stabilin-1
In soft ﬁbrous stroma R = 0.06; р = 0.72 (n = 29) R = 0.39; р = 0.06 (n = 22)
In  coarse ﬁbrous stroma R = 0.19; р = 0.35 (n = 24) R = 0.27; р = 0.89 (n = 12)
“Maximum stromal-and-parenchymal relationship” R = 0.08; р = 0.78 (n = 12) R = −0.35; р = −0.65 (n = 5)
Among parenchymal elements R = −0.94; р = −4.24 (n = 4) R = 0.86; р = 1.73 (n = 3)
In  gaps of ductal tumor structures R = −0.67; р = 0.02 (n = 11) R = 0.5; р = 0.58 (n = 3)
Table 4
The correlation of CD68 expression in the inﬂammatory cell inﬁltrate with the rate of tumor malignancy in patients with the nonspeciﬁc invasive breast cancer.
Macrophage marker expression The rate of tumor malignancy
CD68 Stabilin-1
In soft ﬁbrous stroma R = 0.19; р = 0.35 (n = 25) R = 0.21; р = 0.93 (n = 20)
In  coarse ﬁbrous stroma R = −0.20; р = −0.86 (n = 20) R = −0.23; р = −0.72 (n = 11)
 = 0.52
 = 0.54
 = 0.55
4
p
r
a“Maximum stromal-and-parenchymal relationship” R
Among parenchymal elements R
In  gaps of ductal tumor structures R
. DiscussionTumor associated macrophages are traditionally believed to
ossess mostly tumor supporting role. Studies in animal models
evealed that TAM release factors that stimulate angiogenic switch
nd lymphatic vessel growth (Lin et al., 2006; Riabov et al., 2014;; р = 0.92 (n = 9) R = 0.18; р = 0.32 (n = 5)
; р = 0.92 (n = 4) R = −1.0 (n = 3)
; р = 1.90 (n = 10) R = 1.0 (n = 3)
Iwata et al., 2007; Lin et al., 2007; Yeo et al., 2014). However, accu-
mulating data indicate that in human patients amount of TAM can
also negatively correlate with parameters of tumor progression
(Buddingh et al., 2011; Zhou et al., 2010, Forssell et al., 2007; Ohri
et al., 2009).
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Table  5
Immonohistological assessment of the correlation of CD68+ and stabilin-1+ TAM with lymphatic metastasis in patients with the nonspeciﬁc invasive breast cancer.
Localization The average score of CD68 expression, M±SD The average score of stabilin-1 expression, M ± SD
N0 N+ N0 N+
in soft ﬁbrous stroma 3.5 ± 0.8 (n = 20) 2.8 ± 0.8 (n = 10) 2.7 ± 1.1 (n = 16) 3.0 ± 0.8 (n = 6)
F  = 3.7; p = 0.06 F = 0,39; p = 0.53
in  coarse ﬁbrous stroma 2.2 ± 0.9 (n = 17) 1.7 ± 1.1 (n = 7) 2.2 ± 1.2 (n = 9) 2.7 ± 1.5 (n = 3)
F  = 1.4; p = 0.24 F = 0.27; p = 0.61
“maximum stromal-and-parenchymal relationship” 4.0 ± 0.0 (n = 8) 3.5 ± 1.0 (n = 4) 3.4 ± 1.3 (n = 5)
F  = 2.2; p = 0.16 −(n = 0)
among parenchymal elements 3.3 ± 1.1 (n = 3) 3.0 (n = 1) 1.3 ± 0.3 (n = 3)
F  = 0.06; p = 0.82 −(n = 0)
in  gaps of ductal tumor structures 3.1 ± 1.0 (n = 7) 1.4 ± 0.5 (n = 5) 2.5 ± 2.1 (n = 2) 1.0 (n = 1)
F  = 10.9; p = 0.007 F = 0.33; p = 0.66
Table 6
The correlation of CD68 expression in gaps of ductal tumor structures of the inﬂammatory cell inﬁltrate with lymphatic metastasis quantiﬁed by ImageScope software.
Lymphogenous metastasis CD68 (mean ± SD) р = 0.001 Stabilin-1 (mean±SD) р = 0.93
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(N0 0.34 ± 0.4 
N1  0.1 ± 0.1
Our study for the ﬁrst time assessed amount of TAM in ﬁve dis-
inct morphological compartments of human breast cancer and
emonstrated that amount of TAM in the gaps of ductal tumor
tructures is associated not with increased, but with decreased
bility of tumor to metastasize into lymphatic nodes.
The amounts of TAM, expressing CD68 and stabilin-1 (marker
f alternative macrophage activation) (Kzhyshkowska, 2010;
zhyshkowska et al., 2006a,b) have been evaluated separately,
ince we showed using immunoﬂuorescent staining and confocal
icroscopy, that presence of these two markers only partially over-
ap on TAM, and cells expressing only CD68 or only stabilin-1 may
onstitute around half of total TAM population in breast cancer.
The principal issue of our study was the analysis of TAM in
istinct morphological structures, where morphology can be also
inked to the functional characteristics of these tumor areas.
In human breast cancer ﬁve distinct intratumoral compartments
an be deﬁned. First structure is represented by areas with soft
brous stroma that are in general characterized by pronounced
nﬂammatory inﬁltrates. Stroma has soft ﬁbrous, reticular compo-
ition with the presence of large multicellular complexes (solid,
lveolar structures). This type of stroma is beneﬁcial for invasive
ell growth (Ham and Moon, 2013). Identiﬁed high amounts of
D68+ and stabilin-1+ TAM in the areas with soft ﬁbrous stroma
an be explained by pronounced inﬁltration due to the reticular
orphology that allows formation of multicellular complexes.
Second intratumoral compartment includes areas with coarse
brous stroma that contain collagen ﬁbers and often reveal signs
f hyalinosis. Coarse stroma progressively loses normal functions
ue to impaired synthesis of extracellular matrix proteins (ECM). As
 result, presentation of bioactive molecules to the cells is strongly
ecreased. Moreover, vascular network, leukocyte extravasation
nd motility are impaired in coarse stroma (Campbell et al., 2011;
iro et al., 2012; Ruffell et al., 2012; Tang, 2013). In accordance
o these features we found signiﬁcantly less of both CD68+ and
tabilin-1+ TAM in coarse ﬁbrous stroma compared to their high
mounts in areas with soft ﬁbrous stroma.
High amounts of CD68+ and stabilin-1+ TAM were found it
he third intratumoral compartment—areas of maximum stromal-
nd-parenchymal relationship revealing some similarities with soft
brous stroma. In these areas short ﬁbers and discrete groups of
ells can be found in the context of soft ﬁbrous reticular stroma
nabling efﬁcient binding of cytokines and growth factors by ECM
nd their presentation to cells for optimal cell-stroma interactions
Mahmoud et al., 2012), supporting the accumulation of TAM.0.06 ± 0.2
0.05 ± 0.18
Amount of TAM is signiﬁcantly lower in the fourth intratu-
moral compartment—parenchymal elements, where presence of
single TAM can be explained by general ability of monocyte-derived
cells to inﬁltrate into the areas with signs of chronic inﬂammation
(Lofdahl et al., 2012). In our study the amount of TAM in parenchy-
mal  elements showed no relations to the parameters of tumor
growth.
Finally, ﬁfth compartment includes gaps of ductal tumor struc-
tures, which are the sites of primary proliferation of atypical and
malignant epithelial cells. The striking ﬁndings were the identiﬁ-
cation made both by conventional quantitative immunohistology
and digital quantiﬁcation of the negative correlation of increased
amounts of CD68+ TAM with lymphatic metastasis. Similar ﬁnding
has been recently published for colorectal cancer. Thus, in con-
trast to vast majority of studies demonstrating positive association
between high TAM inﬁltration and LN metastases, low numbers of
CD68+ TAM in tumor invasive front were associated with presence
of LN metastases in colorectal cancer patients suggesting that TAM
subpopulations localized in certain tumor areas are able to delay
LN metastases at least in certain types of cancer (Gulubova et al.,
2013).
Negative correlation of increased amount of CD68+TAM in our
analysis of breast cancer samples can be explained by the ability of
macrophages that are not yet re-programmed by tumor cells and
possess normal migration capacities to inﬁltrate into ductal struc-
tures. The fact that association of CD68+TAM in ductal structures
with decreased lymphatic metastasis is independent on expression
of M2-marker stabilin-1 further supports the hypothesis that duc-
tal TAM are not completely programmed by tumor cells to be highly
tolerogenic and supporting tumor progression including lymphatic
metastasis. Moreover, we can hypothesize that other anti-tumor
activities might be found in the future in the ductal TAM that pri-
marily attempt to recognize transformed cells and inhibit tumor
progression at the place of origin. Most interesting will be identi-
ﬁcation in future the origin of these TAM that keep them open for
plastic programming in response to tumor microenvironment.
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